Skip to content

Dr. Gearóid Tuohy

Analysis reports the treatment burden of intravitreal anti-VEGF injections among a Norwegian cohort of patients and caregivers on nAMD.

Researchers at the Institute of Basic Medical Sciences, University of Oslo, the Norwegian Association of the Blind and Partially Sighted, Oslo, and Roche Norway (F Hoffmann-La… Read More »Analysis reports the treatment burden of intravitreal anti-VEGF injections among a Norwegian cohort of patients and caregivers on nAMD.

US “LIGHTSITE III” clinical trial data on photo-biomodulation (PBT) treatment of dry AMD has reported vision improvement for 24 months.

A US company, LumiThera Inc., based in Seattle, WA has reported summary trial data on photo-biomodulation, termed “LIGHTSITE III” study, conducted by a multi-centre clinical… Read More »US “LIGHTSITE III” clinical trial data on photo-biomodulation (PBT) treatment of dry AMD has reported vision improvement for 24 months.

Two new RP/LCA-specific instruments have reported strong evidence for psychometric validity on measures with RP/LCA adults and caregivers of children.

Researchers led by clinical scientists at the Department of Clinical Neurosciences, University of Oxford, UK, has reported that, previously, there have been no disease-specific instruments… Read More »Two new RP/LCA-specific instruments have reported strong evidence for psychometric validity on measures with RP/LCA adults and caregivers of children.

Antisense oligonucleotide (AON) therapy for Stargardt disease type 1 (STGD1) provides a proof of concept with effective restoration of correct ABCA4 transcript splicing. 

Researchers at ProQR Therapeutics, an RNA company based in Leiden, the Netherlands, and with researchers at Radboud University Medical Center in Nijmegen, have reported results… Read More »Antisense oligonucleotide (AON) therapy for Stargardt disease type 1 (STGD1) provides a proof of concept with effective restoration of correct ABCA4 transcript splicing. 

Opus Genetics Inc., has announced new data on the potential of gene therapy treatments from RDH12- and MERTK-associated retinal degenerations.

Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced new data on preparing AAV-based gene therapy programs to… Read More »Opus Genetics Inc., has announced new data on the potential of gene therapy treatments from RDH12- and MERTK-associated retinal degenerations.